Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
China · Delayed Price · Currency is CNY 11.77
-0.23 (-1.92%)
Nov 6, 2026, 11:15 AM CST
SHA:688488 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 715.79 | 718.18 | 415.54 | 409.06 | 242.86 | 254.97 |
Other Revenue | 0.99 | 0.99 | 2.26 | 2.3 | 1.36 | 0.74 |
| 716.78 | 719.17 | 417.8 | 411.36 | 244.22 | 255.71 | |
Revenue Growth | 6.77% | 72.13% | 1.57% | 68.44% | -4.49% | -11.54% |
Cost of Revenue | 253.15 | 255.83 | 224.53 | 245.01 | 172.18 | 181.33 |
Gross Profit | 463.63 | 463.34 | 193.28 | 166.36 | 72.04 | 74.38 |
Selling, General & Admin | 324.08 | 336.12 | 251.95 | 199.69 | 167.57 | 88.24 |
Research & Development | 76.18 | 87.37 | 89.89 | 63.18 | 63.91 | 47.67 |
Other Operating Expenses | 0.9 | 4.72 | -3.1 | 5.78 | 3.33 | 3.31 |
Operating Expenses | 401.27 | 428.58 | 335.38 | 272.39 | 243.68 | 136.73 |
Operating Income | 62.37 | 34.76 | -142.11 | -106.03 | -171.64 | -62.34 |
Interest Expense | -3.7 | -15.62 | -15.36 | -11.76 | -3.92 | -0.25 |
Interest & Investment Income | 0.35 | 2.19 | 9.49 | 14.1 | 9.67 | 10.47 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | 0.02 | -0.1 | 0.88 | -0.2 |
Other Non Operating Income (Expenses) | -13.8 | 0.13 | -1.98 | -0.08 | -0.11 | -0.09 |
EBT Excluding Unusual Items | 45.12 | 21.36 | -149.95 | -103.88 | -165.11 | -52.41 |
Impairment of Goodwill | - | - | -0.63 | - | - | - |
Gain (Loss) on Sale of Investments | -4.36 | 17.48 | 10.76 | 1.54 | 7.19 | 0.31 |
Gain (Loss) on Sale of Assets | 1.2 | -0.09 | -0.43 | -0.06 | -0.28 | 1.58 |
Asset Writedown | 2.94 | - | -28.33 | - | - | - |
Other Unusual Items | -12.47 | -14.11 | 2.58 | 10.3 | 15.82 | 8.25 |
Pretax Income | 32.43 | 24.64 | -166 | -92.09 | -142.38 | -42.27 |
Income Tax Expense | 8.76 | 16.56 | -27.16 | -16.02 | -18.29 | -12.29 |
Earnings From Continuing Operations | 23.66 | 8.08 | -138.84 | -76.07 | -124.09 | -29.99 |
Minority Interest in Earnings | -16.54 | -27.62 | -2.37 | - | - | - |
Net Income | 7.12 | -19.53 | -141.2 | -76.07 | -124.09 | -29.99 |
Net Income to Common | 7.12 | -19.53 | -141.2 | -76.07 | -124.09 | -29.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 462 | 421 | 415 | 423 | 414 | 428 |
Shares Outstanding (Diluted) | 462 | 421 | 415 | 423 | 414 | 428 |
Shares Change | 33.66% | 1.36% | -1.73% | 2.17% | -3.44% | 7.71% |
EPS (Basic) | 0.02 | -0.05 | -0.34 | -0.18 | -0.30 | -0.07 |
EPS (Diluted) | 0.02 | -0.05 | -0.34 | -0.18 | -0.30 | -0.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.24 | -30.3 | -82.06 | -237.43 | -232.85 | -107.15 |
Free Cash Flow Per Share | 0.00 | -0.07 | -0.20 | -0.56 | -0.56 | -0.25 |
Gross Margin | 64.68% | 64.43% | 46.26% | 40.44% | 29.50% | 29.09% |
Operating Margin | 8.70% | 4.83% | -34.01% | -25.78% | -70.28% | -24.38% |
Profit Margin | 0.99% | -2.72% | -33.80% | -18.49% | -50.81% | -11.73% |
Free Cash Flow Margin | 0.03% | -4.21% | -19.64% | -57.72% | -95.34% | -41.90% |
EBITDA | 118.05 | 87.11 | -94.22 | -64.1 | -138.39 | -35.09 |
EBITDA Margin | 16.47% | 12.11% | -22.55% | -15.58% | -56.66% | -13.72% |
D&A For EBITDA | 55.68 | 52.35 | 47.89 | 41.93 | 33.26 | 27.25 |
EBIT | 62.37 | 34.76 | -142.11 | -106.03 | -171.64 | -62.34 |
EBIT Margin | 8.70% | 4.83% | -34.01% | -25.78% | -70.28% | -24.38% |
Effective Tax Rate | 27.02% | 67.20% | - | - | - | - |
Revenue as Reported | 166.77 | 719.17 | 417.8 | 411.36 | 244.22 | 255.71 |
Advertising Expenses | - | - | - | - | 2.69 | 1.56 |